MedTrace Logo

Rosiglitazone Versus a Sulfonylurea On Progression Of Atherosclerosis In Patients With Heart Disease And Type 2 Diabetes

NCT00116831 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 672

Last updated 2017-03-23

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to test the safety and effectiveness of rosiglitazone against a sulfonylurea in reducing or slowing the development of atherosclerosis in the blood vessels of the heart.

Conditions

Interventions

DRUG

Glipizide

oral anti-diabetic medication

DRUG

rosiglitazone maleate

oral antidiabetic medication

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-01-31
Primary Completion
2008-08-31
Completion
2008-08-31

Countries

  • United States
  • Argentina
  • Brazil
  • Canada
  • Czechia
  • France
  • Germany
  • Greece
  • Hong Kong
  • India
  • Italy
  • Latvia
  • Mexico
  • Netherlands
  • Poland
  • Russia
  • South Korea
  • Spain
  • Sweden
  • Thailand

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00116831 on ClinicalTrials.gov